Annexon, Inc. (NASDAQ:ANNX) Director William H. Carson Purchases 3,200 Shares

Annexon, Inc. (NASDAQ:ANNX) Director William H. Carson purchased 3,200 shares of the business’s stock in a transaction on Monday, July 1st. The stock was acquired at an average price of $5.00 per share, for a total transaction of $16,000.00. Following the completion of the purchase, the director now owns 12,800 shares of the company’s stock, valued at $64,000. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Annexon Trading Down 9.6 %

Shares of NASDAQ ANNX traded down $0.48 during midday trading on Tuesday, reaching $4.57. 1,395,099 shares of the company were exchanged, compared to its average volume of 2,207,092. Annexon, Inc. has a 1 year low of $1.57 and a 1 year high of $8.40. The stock has a fifty day simple moving average of $4.99 and a 200 day simple moving average of $5.07. The stock has a market cap of $421.85 million, a P/E ratio of -3.22 and a beta of 1.29.

Annexon (NASDAQ:ANNX) last released its quarterly earnings results on Monday, May 13th. The company reported ($0.21) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.32) by $0.11. As a group, analysts forecast that Annexon, Inc. will post -0.98 earnings per share for the current year.

Hedge Funds Weigh In On Annexon

A number of hedge funds and other institutional investors have recently made changes to their positions in ANNX. Kennedy Capital Management LLC purchased a new stake in Annexon in the 3rd quarter valued at approximately $2,306,000. Sectoral Asset Management Inc. boosted its holdings in Annexon by 33.2% in the 3rd quarter. Sectoral Asset Management Inc. now owns 898,785 shares of the company’s stock valued at $2,121,000 after purchasing an additional 224,156 shares in the last quarter. SG Americas Securities LLC boosted its holdings in Annexon by 14.1% in the 4th quarter. SG Americas Securities LLC now owns 25,335 shares of the company’s stock valued at $115,000 after purchasing an additional 3,123 shares in the last quarter. Tower Research Capital LLC TRC boosted its holdings in Annexon by 53.2% in the 4th quarter. Tower Research Capital LLC TRC now owns 11,924 shares of the company’s stock valued at $54,000 after purchasing an additional 4,141 shares in the last quarter. Finally, Bain Capital Life Sciences Investors LLC boosted its holdings in Annexon by 41.4% in the 4th quarter. Bain Capital Life Sciences Investors LLC now owns 8,061,719 shares of the company’s stock valued at $36,600,000 after purchasing an additional 2,359,793 shares in the last quarter.

Analyst Ratings Changes

ANNX has been the topic of several research reports. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Annexon in a report on Wednesday, June 5th. JPMorgan Chase & Co. raised their price objective on Annexon from $11.00 to $13.00 and gave the stock an “overweight” rating in a report on Monday, April 1st. Bank of America raised their price objective on Annexon from $7.00 to $10.00 and gave the stock a “buy” rating in a report on Thursday, March 28th. HC Wainwright reaffirmed a “buy” rating and set a $30.00 price objective on shares of Annexon in a report on Tuesday, June 4th. Finally, Wells Fargo & Company dropped their price objective on Annexon from $12.00 to $10.00 and set an “overweight” rating on the stock in a report on Wednesday, May 15th. Six investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock presently has an average rating of “Buy” and an average price target of $15.33.

Annexon Company Profile

Annexon, Inc, a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis.